Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 6

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

Authors Montepaone M, Lubrano E, Carboni A, Spadaro A

Received 16 October 2013

Accepted for publication 18 November 2013

Published 20 February 2014 Volume 2014:6 Pages 7—13

DOI https://doi.org/10.2147/OARRR.S56048

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3


Monica Montepaone,1 Ennio Lubrano,2 Alessia Carboni,1 Antonio Spadaro1

1Unità Operativa Complessa di Reumatologia, Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, 2Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy

Abstract: Psoriatic arthritis (PsA) is a chronic inflammatory arthritis and considered to be a less severe condition than rheumatoid arthritis. PsA patients have been treated for a long time with a number of different agents, from non-steroidal anti-inflammatory drugs to one or more disease-modifying antirheumatic drugs. In the last decade, recognition of the central role of tumor necrosis factor-alpha (TNFα) in the immunopathogenesis of many rheumatic diseases, including PsA, has led to the development of TNFα blockers. In PsA, these agents are uniquely efficacious in the treatment of different patterns of the disease, as well as slowing progression of erosive damage in the peripheral joints. However, a significant number of patients withdraw from therapy because of failure or poor tolerability. Among the novel therapeutic targets, interleukin (IL)-23/IL-12 has been investigated for the treatment of chronic inflammatory disease. In particular, ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells. Ustekinumab has been approved only for treatment of chronic plaque psoriasis, but also represents an interesting agent for treatment of PsA.

Keywords: ustekinumab, psoriatic arthritis, psoriasis, interleukin-12, interleukin-23

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]